University of Southern California
USC Norris Comprehensive Cancer Center
If you are a patient, please contact Keck Medical Center of USC at 800-USC-CARE.

Trial 0S-10-2


Prospective, Longitudinal, Multi-National Registry of Patients with Newly Diagnosed Peripheral T-Cell Lymphoma.

Type: Observational
Phase: Observational
Status: Closed to Accrual with Ongoing Follow-up
Treatments:
Randomized: No
Defintions of terms and FAQ about clinical trials.
Trial Leaders/Researchers:  Anil Tulpule, M.D.
Other Trial Staff:  Christine Duran, D.M., TehChun Wang, R.N., Teresa Olea, R.N.

Staff may log in to see study documents.


You may participate in this study if:
 Requirement
1Aggressive natural killer (NK)-cell leukemia
2Adult T-cell lymphoma/leukemia (human T-cell leukemia virus [HTLV] 1+)
3Angioimmunoblastic T-cell lymphoma
4Anaplastic large cell lymphoma (ALCL), primary systemic type (ALK+, ALK-)
5PTCL, not otherwise specified
6T/NK-cell lymphoma, nasal type
7Enteropathy-type intestinal lymphoma
8Hepatosplenic T-cell lymphoma
9Subcutaneous panniculitis T-cell lymphoma
10Transformed mycosis fungoides (at diagnosis of transformation)
11T-cell prolymphocytic leukemia (T-PLL)
12Cutaneous T-cell lymphoma
13Cutaneous aggressive CD8+ T-cell lymphoma
14Hematodermic neoplasms (blastic plasmacytoid dendritic cell neoplasm)
15Systemic Epstein Barr Virus (EBV)+ T-cell lymphomas (T-cell lymphoproliferative disorders of childhood)
16Other T-Cell lymphomas not excluded


You may not participate in this study if:
1Precursor T/NK neoplasms
2T-cell large granular lymphocytic leukemia
3Mycosis fungoides, other than transformed mycosis fungoides
4Sézary syndrome
5Primary cutaneous CD30+ disorders: ALCL and lymphomatoid papulosis



For further information on a study, please contact the Clinical Investigation Support Office at (323) 865-0451, or clinical.trials@med.usc.edu.

To schedule a consultation with the hospital, please call our New Patient Referrals Office at (323) 865-3111.